Alan Breier

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach
    A Breier
    Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Synapse 29:142-7. 1998
  2. ncbi Dopamine D2 receptor density and personal detachment in healthy subjects
    A Breier
    Experimental Therapeutics Branch, NIMH, Bethesda, MD, USA
    Am J Psychiatry 155:1440-2. 1998
  3. ncbi A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia
    Alan Breier
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 1748, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:441-8. 2002
  4. ncbi Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
  5. ncbi Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years
    Peter D Feldman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 64:998-1004. 2003
  6. ncbi A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Ind 46225, USA
    Arch Gen Psychiatry 60:1218-26. 2003
  7. ncbi Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 60:1079-88. 2003
  8. ncbi Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
    Todd M Sanger
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Affect Disord 73:155-61. 2003
  9. ncbi Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp
    Margaret Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 88:5875-80. 2003
  10. ncbi Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid
    Madhav A Namjoshi
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Bldg 75 05, DC1758, Indianapolis, IN 46285, USA
    J Affect Disord 81:223-9. 2004

Detail Information

Publications47

  1. ncbi Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach
    A Breier
    Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Synapse 29:142-7. 1998
    ..The implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed...
  2. ncbi Dopamine D2 receptor density and personal detachment in healthy subjects
    A Breier
    Experimental Therapeutics Branch, NIMH, Bethesda, MD, USA
    Am J Psychiatry 155:1440-2. 1998
    ..The purpose of this study was to examine the relationship between the personality trait involving personal detachment and dopamine D2 receptor specific binding in healthy subjects...
  3. ncbi A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia
    Alan Breier
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 1748, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:441-8. 2002
    ..An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia...
  4. ncbi Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
    ..The efficacy and safety of olanzapine were compared with those of ziprasidone...
  5. ncbi Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years
    Peter D Feldman
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 64:998-1004. 2003
    ..This analysis compares the efficacy of risperidone and olanzapine in controlling negative and positive symptoms of chronic psychosis in older patients...
  6. ncbi A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Ind 46225, USA
    Arch Gen Psychiatry 60:1218-26. 2003
    ..This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania...
  7. ncbi Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 60:1079-88. 2003
    ....
  8. ncbi Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
    Todd M Sanger
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Affect Disord 73:155-61. 2003
    ..CONCLUSIONS: These results indicate that olanzapine was effective in reducing symptoms of mania and well tolerated in patients with bipolar I disorder with a rapid-cycling course...
  9. ncbi Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp
    Margaret Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 88:5875-80. 2003
    ..In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone...
  10. ncbi Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid
    Madhav A Namjoshi
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Bldg 75 05, DC1758, Indianapolis, IN 46285, USA
    J Affect Disord 81:223-9. 2004
    ..The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder...
  11. ncbi Olanzapine versus divalproex in the treatment of acute mania
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1011-7. 2002
    ..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial...
  12. ncbi Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States
    Peter D Feldman
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Med Dir Assoc 5:38-46. 2004
    ..The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications...
  13. ncbi Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia
    Walter G Deberdt
    Lilly Research Laboratories, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 13:722-30. 2005
    ..The authors compared efficacy of olanzapine versus placebo and risperidone as measured by the Neuropsychiatric Inventory and Clinical Global Impression-Severity of Psychosis scale in patients with dementia-related psychosis...
  14. ncbi Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach
    Melissa Spann
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychiatr Res 43:561-7. 2009
    ..Sample size was reduced from 311 to 156 patients, thereby decreasing the number of patients exposed to placebo from 54 to 30 and the number exposed to the active control with a known side effect from 126 to 60...
  15. ncbi Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
    Karena M Meehan
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 26:494-504. 2002
    ..Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation...
  16. ncbi Amantadine for weight gain associated with olanzapine treatment
    Walter Deberdt
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 15:13-21. 2005
    ..Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy...
  17. ncbi Diabetes mellitus and antipsychotic treatment in the United Kingdom
    Christopher Carlson
    Eli Lilly and Company, Indianapolis, IN, USA
    Eur Neuropsychopharmacol 16:366-75. 2006
    ..CONCLUSION: Consistent with other epidemiology studies, this study supports an increased risk of developing diabetes during treatment with antipsychotics...
  18. ncbi Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia
    Caleb M Adler
    Experimental Therapeutics Branch, National Institute of Mental Health/NIH, Bethesda, MD, USA
    Neuropsychopharmacology 26:295-300. 2002
    ..More research is needed to unravel the neurobiology of this debilitating disorder...
  19. ncbi Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 1 Corporate Plaza, DC 6314, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 13:81-5. 2003
    ..Nizatidine 300 mg b.i.d. may have an early transient effect in limiting the weight gain, but this potential early effect appeared to be diminished or eliminated by 16 weeks...
  20. ncbi Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder
    David H Adams
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Hum Psychopharmacol 23:267-74. 2008
    ..To test association of dopamine receptor D3 (DRD-3) gene polymorphisms with olanzapine response in genetic samples from a registration phase clinical trial...
  21. ncbi Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease
    Alan Breier
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 52:438-45. 2002
    ..Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis...
  22. ncbi Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial
    Madhav A Namjoshi
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN, USA
    J Affect Disord 69:109-18. 2002
    ..The objectives of this study were to determine the economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in patients diagnosed with mania...
  23. ncbi Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Br J Psychiatry Suppl 47:S94-101. 2004
    ..In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications...
  24. ncbi Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo
    Margaret O Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2918-23. 2002
    ..The results of this study do not support the hypothesis that olanzapine or risperidone directly impair pancreatic beta-cell function...
  25. ncbi Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
    ..CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes...
  26. ncbi Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database
    Zhongyun Zhao
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    CNS Drugs 18:157-64. 2004
    ..To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia...
  27. ncbi Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics
    Mauricio Silva de Lima
    Eli Lilly Brazil, Sao Paulo, Brazil
    J Clin Psychiatry 66:831-8. 2005
    ..To assess the effectiveness of olanzapine for treating schizophrenia and to assess if olanzapine promotes a better quality of life than first-generation antipsychotics (FGAs)...
  28. ncbi Wayne Fenton's impact on industry
    Alan Breier
    Schizophr Bull 33:1154-5. 2007
  29. ncbi Developing drugs for cognitive impairment in schizophrenia
    Alan Breier
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Bull 31:816-22. 2005
    ..It is concluded that close collaboration among academia, the National Institutes of Health, regulatory bodies, and industry will be important to advance the goal of developing drugs for this important condition...
  30. ncbi Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes: response to Lean and Pajonk
    Thomas Hardy
    Diabetes Care 26:3200-1. 2003
  31. ncbi Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo
    Igor Elman
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuropsychopharmacology 27:293-300. 2002
    ..Our data suggest that both risperidone and clozapine elevate plasma NE levels via enhanced neurotransmitter spillover, with risperidone producing a smaller effect...
  32. ncbi Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population
    Ralph E Hoffman
    Yale New Haven Psychiatric Hospital, 184 Liberty Street LV108, New Haven, CT 06519, USA
    Br J Psychiatry 191:355-6. 2007
    ..no drug) and length of speech illusion, with the latter strongly predicting subsequent conversion during medication-free intervals but not during olanzapine treatment...
  33. ncbi Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia
    John P Houston
    J Clin Psychopharmacol 27:520-3. 2007
  34. ncbi A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
    John B Buse
    Diabetes Care Center and Division of General Medicine, University of North Carolina School of Medicine, 5039 Old Clinic Building, CB 7110, Chapel Hill, NC 27599 7110, USA
    J Clin Epidemiol 56:164-70. 2003
    ..An increased risk of developing diabetes compared with the AdvancePCS general patient population was observed during treatment with conventional or atypical antipsychotics...
  35. ncbi Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
    Istvan Bitter
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Prog Neuropsychopharmacol Biol Psychiatry 28:173-80. 2004
    ..Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia...
  36. ncbi A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy
    Padraig Wright
    Lilly Research Centre, Eli Lilly and Co. Ltd, Surrey, United Kingdom
    Clin Ther 25:1420-8. 2003
    ..The combination of IM and PO olanzapine may help improve the treatment of acutely agitated patients with schizophrenia...
  37. ncbi One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Schizophr Res 81:1-15. 2006
    ..Haloperidol-treated patients improved only on domains of learning/memory. However, patients able to remain in treatment for the entire 52 weeks benefited more from olanzapine or risperidone treatment than haloperidol treatment...
  38. ncbi The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes
    Celso Arango
    Maryland Psychiatric Research Center, Department of Psychariatry, University of Maryland, MD 21228, USA
    Am J Psychiatry 160:1421-7. 2003
    ....
  39. ncbi Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 54:453-64. 2003
    ..Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment...
  40. ncbi Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment
    Padraig Wright
    Clinical Neuroscience, Lilly Research Centre, Eli Lilly and Company, Surrey, UK
    Can J Psychiatry 48:716-21. 2003
    ..In general, more EPS were observed during treatment with i.m. haloperidol than with i.m. olanzapine...
  41. ncbi Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
    Peter Paul De Deyn
    Department of Neurology, Middelheim Hospital, University of Antwerp, Antwerp, Belgium
    Int J Geriatr Psychiatry 19:115-26. 2004
    ..5 mg dose was a reasonable starting dose. Olanzapine at 7.5 mg/day significantly decreased psychosis and overall behavioral disturbances (NPI/NH, BPRS) and was well tolerated...
  42. ncbi Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder
    Vivian Mitropoulou
    Department of Psychiatry, Mt Sinai School of Medicine Clinical Reseach Center, New York, NY 10029, USA
    Schizophr Res 70:27-31. 2004
    ..We hypothesized that SPD patients would demonstrate comparable or lower DA and HPA responses after 2-DG to HV...
  43. ncbi Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia
    Igor Elman
    Department of Psychiatry, McLean Hospital and Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 176:369-75. 2004
    ..Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function...
  44. ncbi Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis
    Thomas H McGlashan
    Department of Psychiatry, Yale University School of Medicine, 301 Cedar St, New Haven, CT 06519, USA
    Am J Psychiatry 163:790-9. 2006
    ..This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia...
  45. ncbi Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Clin Neuropharmacol 28:215-9. 2005
    ....
  46. ncbi Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia
    Igor Elman
    Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    J Psychopharmacol 17:317-23. 2003
    ....
  47. ncbi Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
    John H Krystal
    Schizophrenia Biological Research Center 116 A, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Psychopharmacology (Berl) 179:303-9. 2005
    ..Some of the behavioral consequences of deficits in N-methyl-D-aspartate (NMDA) glutamate receptor function are thought to arise from the disinhibition of cortical glutamatergic circuitry...